testos Cancer Research Results

testos, testosterone: Click to Expand ⟱
Source:
Type:
Hormone therapy — slows cancer growth by lowering testosterone levels in the body.
"shaking up prostate cancer with high-dose testosterone makes it more vulnerable to other treatments."
testosterone-levels-in-men-with-prostate-cancer" >There is a higher incidence of prostate cancer among men with low testosterone.

Prostate cancer is highly sensitive to androgenic stimulation. Testosterone—and more potently, its derivative dihydrotestosterone (DHT)—binds to the androgen receptor (AR) in prostate cells, which can drive the growth and survival of both normal and malignant cells.

Castration-Resistant Prostate Cancer (CRPC):

Even after testosterone levels are medically reduced, some prostate cancers continue to thrive by adapting their AR pathway. CRPC often signals a transition to a more aggressive, treatment-resistant state.
Scientific Papers found: Click to Expand⟱
7988- itraC,    Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study
- Trial, Pca, NA
PSA↓, Nine patients (47%) experienced any PSA decline (mean decline 25.0%, range 2%-60%) by week 12.
toxicity↝, The most common adverse events were edema (52%), fatigue (38%), hypertension (24%), and hypokalemia (24%).
testos∅, Itraconazole modulates serum PSA levels without lowering serum testosterone.
toxicity↝, However, the magnitude of effect is modest, and treatment carries risk of toxicities associated with mineralocorticoid excess.

8013- itraC,    High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer
- Case Report, Pca, NA
*AntiFungal↑, Itraconazole is an FDA-approved antifungal drug used in the treatment of various mycoses that was repurposed as an antineoplastic agent after a screening effort identified that it could potently inhibit Hedgehog (Hh) pathway signaling in cancer.
antiNeop↑,
HH↓,
Dose↝, a phase II clinical trial suggested that itraconazole prescribed at high doses (600 mg per day) may have a role as an antineoplastic agent in men with metastatic castration-resistant prostate cancer (CRPC) who had not previously received chemotherapy
OS↑, In this trial, modest clinical activity using high-dose itraconazole in this setting was demonstrated as evidenced by longer PSA-progression-free survival and clinical/radiographic-progression-free survival compared to historical controls.
testos∅, Of note, treatment with itraconazole did not appear to have a significant effect on testosterone levels in these men with CRPC, suggesting that its clinical activity (unlike that of ketoconazole) may be independent of androgen modulation.
Dose↝, At initiation of treatment with itraconazole (300 mg, twice daily), the patient’s PSA level was 34.3 ng/mL and his testosterone level was in the non-castrate range
PSA↓, Following only one month of treatment with itraconazole, the PSA declined to 20.1 ng/mL, while the patient did report some grade-1 fatigue.
other↝, After 5 months of treatment, and despite a persistent PSA response with minimal adverse events, the patient developed asymptomatic hyperbilirubinemia necessitating discontinuation of itraconazole.
other↝, While the bilirubin level normalized after stopping itraconazole, this was accompanied by a subsequent increase in PSA level to 29.4 ng/mL, approximately one month after drug discontinuation.
HH↓, Inhibition of the Hedgehog pathway may mediate the clinical activity of itraconazole.


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Transcription & Epigenetics(tgid=7) ⓘ

other↝, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HH↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

PSA↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

testos∅, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

antiNeop↑, 1,   OS↑, 1,   toxicity↝, 2,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: testos, testosterone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:458  State#:%  Dir#:6
  wNotes=on  sortOrder:rid,rpid

 

Home Page